These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 28873367)
21. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia. Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322 [TBL] [Abstract][Full Text] [Related]
22. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Platt MY; Fathi AT; Borger DR; Brunner AM; Hasserjian RP; Balaj L; Lum A; Yip S; Dias-Santagata D; Zheng Z; Le LP; Graubert TA; Iafrate AJ; Nardi V J Mol Diagn; 2015 Nov; 17(6):661-8. PubMed ID: 26331834 [TBL] [Abstract][Full Text] [Related]
23. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. DiNardo CD; Jabbour E; Ravandi F; Takahashi K; Daver N; Routbort M; Patel KP; Brandt M; Pierce S; Kantarjian H; Garcia-Manero G Leukemia; 2016 Apr; 30(4):980-4. PubMed ID: 26228814 [No Abstract] [Full Text] [Related]
24. TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Kharfan-Dabaja MA; Komrokji RS; Zhang Q; Kumar A; Tsalatsanis A; Perkins J; Nishihori T; Field T; Al Ali N; Mishra A; Sallman D; Salem KZ; Zhang L; Moscinski L; Fernandez HF; Lancet J; List A; Anasetti C; Padron E Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):753-758. PubMed ID: 28687222 [TBL] [Abstract][Full Text] [Related]
25. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation. Kunadt D; Stasik S; Metzeler KH; Röllig C; Schliemann C; Greif PA; Spiekermann K; Rothenberg-Thurley M; Krug U; Braess J; Krämer A; Hochhaus A; Scholl S; Hilgendorf I; Brümmendorf TH; Jost E; Steffen B; Bug G; Einsele H; Görlich D; Sauerland C; Schäfer-Eckart K; Krause SW; Hänel M; Hanoun M; Kaufmann M; Wörmann B; Kramer M; Sockel K; Egger-Heidrich K; Herold T; Ehninger G; Burchert A; Platzbecker U; Berdel WE; Müller-Tidow C; Hiddemann W; Serve H; Stelljes M; Baldus CD; Neubauer A; Schetelig J; Thiede C; Bornhäuser M; Middeke JM; Stölzel F; J Hematol Oncol; 2022 Sep; 15(1):126. PubMed ID: 36064577 [TBL] [Abstract][Full Text] [Related]
26. IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Zou Y; Zeng Y; Zhang DF; Zou SH; Cheng YF; Yao YG Biochem Biophys Res Commun; 2010 Nov; 402(2):378-83. PubMed ID: 20946881 [TBL] [Abstract][Full Text] [Related]
27. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms. Molenaar RJ; Thota S; Nagata Y; Patel B; Clemente M; Przychodzen B; Hirsh C; Viny AD; Hosano N; Bleeker FE; Meggendorfer M; Alpermann T; Shiraishi Y; Chiba K; Tanaka H; van Noorden CJ; Radivoyevitch T; Carraway HE; Makishima H; Miyano S; Sekeres MA; Ogawa S; Haferlach T; Maciejewski JP Leukemia; 2015 Nov; 29(11):2134-42. PubMed ID: 25836588 [TBL] [Abstract][Full Text] [Related]
28. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213 [TBL] [Abstract][Full Text] [Related]
29. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020 [TBL] [Abstract][Full Text] [Related]
30. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122 [TBL] [Abstract][Full Text] [Related]
34. [Clinical characteristics in adult acute myeloid leukemia with isocitrate dehydrogenase gene mutation]. Wang RX; Wu DP; Chen SN; He J; Xu Y; Wang XL; Yin J; Tian H; Tian XP; Sun AN Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(10):751-5. PubMed ID: 23755812 [TBL] [Abstract][Full Text] [Related]
35. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. Ahmadi R; Stockhammer F; Becker N; Hohlen K; Misch M; Christians A; Dictus C; Herold-Mende C; Capper D; Unterberg A; von Deimling A; Wick W; Hartmann C J Neurooncol; 2012 Aug; 109(1):15-22. PubMed ID: 22528790 [TBL] [Abstract][Full Text] [Related]
36. IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. Zou P; Xu H; Chen P; Yan Q; Zhao L; Zhao P; Gu A PLoS One; 2013; 8(7):e68782. PubMed ID: 23894344 [TBL] [Abstract][Full Text] [Related]
37. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes. Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030 [TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631 [TBL] [Abstract][Full Text] [Related]
39. Adverse impact of IDH1 and IDH2 mutations in primary AML: experience of the Spanish CETLAM group. Nomdedéu J; Hoyos M; Carricondo M; Esteve J; Bussaglia E; Estivill C; Ribera JM; Duarte R; Salamero O; Gallardo D; Pedro C; Aventin A; Brunet S; Sierra J Leuk Res; 2012 Aug; 36(8):990-7. PubMed ID: 22520341 [TBL] [Abstract][Full Text] [Related]
40. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS). Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]